Summary
The kinetics of dextropropoxyphene (DP) and its main metabolite norpropoxyphene (NP) were studied in 6 healthy male subjects after a single oral dose of 195 mg DP HCl, and during and after 12 daily single oral doses of 195 mg DP HCl. The kinetics varied up to five-fold between individuals after the single dose, the apparent mean elimination half-life (t1/2) was 16 h for DP and 29 h for NP. The mean apparent overall plasma clearance (CL) for DP was 2.61/min. There was no systematic difference in DP clearance between the single and multiple doses, but the accuracy of individual predictions from single to multiple doses was poor, probably because of imprecise determinations of the AUC and t1/2 in the single dose experiments. The individual correlation between single and multiple dose kinetics was good for NP, although the predicted plasma levels during steady state were significantly higher than the observed levels (mean AUCss/AUCsd: 0.81). There was no sign of saturation kinetics on repeated administration. In fact, autoinduction, resulting in significantly lower plasma concentrations after treatment for 1 week was found for NP and was indicated for DP. On discontinuing DP after 12 days of treatment, the apparent mean t1/2 of DP was 23 h and of NP 25 h.
Similar content being viewed by others
References
Finkle BS, McCloskey KL, Kiplinger GF, Bennet IF (1976) A national assessment of propoxyphene in post mortem medicolegal investigation. J Forensic Sci 21: 706–742
Gibaldi M, Weintraub H (1971) Some considerations as to the determination and significance of biologic half-life. J Pharm Sci 60: 624–626
Gram LF, Schou J, Way WL, Heltberg J, Bodin NO (1979) D-propoxyphene kinetics after single oral and intravenous doses in man. Clin Pharmacol Ther 26: 473–482
Gram LF, Schou J, Heltberg J, Way WL (1980) D-propoxyphene single dose kinetics in a subject taking phenobarbital. Acta Pharmacol Toxicol 46: 395–397
Gram LF, Schmidt K, Christensen FN, Schou J (1984) d-propoxyphene kinetics in man: Significance of a deep third compartment. Eur J Clin Pharmacol 26: 749–752
Holland DR, Steinberg MI (1979) Electrophysiologic properties of propoxyphene and norpropoxyphene in canine cardiac conducting tissues in vitro and in vivo. Toxicol Appl Pharmacol 47: 123–133
Inturrisi CE, Wayne AC, Verebely K, Dayton HE, Woody GE, O'Brien CP (1982) Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene. Clin Pharmacol Ther 31: 157–167
Lund-Jacobsen H (1978) Cardio-respiratory toxicity of propoxyphene and norpropoxyphene in conscious rabbits. Acta Pharmacol Toxicol 42: 171–178
McMahon RE, Ridolfo AS, Culp HW, Wolen RL, Marshall FJ (1971) The fate of radiocarbon-labeled propoxyphene in rat, dog and human. Toxicol Appl Pharmacol 19: 427–444
McMahon RE, Sullivan HR, Due SL, Marshall FJ (1973) The metabolite pattern of d-propoxyphene in man. The use of heavy isotopes in drug disposition studies. Life Sci 12: 463–473
Nickander R, Smits SE, Steiberg MI (1977) Propoxyphene and norpropoxyphene: Pharmacological and toxic effects in animals. J Pharmacol Exp Ther 200: 245–253
Perrier D, Gibaldi M (1972) Influence of first-pass effect on the systemic availability of propoxyphene. J Clin Pharmacol 12: 449–452
Peterson GR, Hostetler RM, Lehman T, Covault HP (1979) Acute inhibition of oxidative drug metabolism by propoxyphene (Darvon). Biochem Pharmacol 28: 1783–1789
Schou J, Angelo H, Dam W, Jensen K, Christensen JM (1978) Pharmacokinetics of dextropropoxyphene in acute poisoning. Arch Toxicol 1 [Suppl]: 343–346
Thayssen P, Bjerre M, Kragh-Sørensen P, Møller M, Pedersen OL, Kristensen CB, Gram LF (1981) Cardiovascular effects of imipramine and nortriptyline in elderly patients. Psychopharmacology 74: 360–364
Verebely K, Inturrisi CE (1974) Disposition of propoxyphene and norpropoxyphene in man after a single oral dose. Clin Pharmacol Ther 15: 302–309
Wagner JG, Welling PG, Roth SB, Sakmar E, Lee KP, Walker JE (1972a) Plasma concentrations of propoxyphene in man. Int J Clin Pharmacol 5: 371–380
Wagner JG, Welling PG, Roth SB, Sakmar E, Lee KP, Walker JE (1972b) Plasma concentrations of propoxyphene in man. Int J Clin Pharmacol 5: 381–388
Wolen RL, Gruber CM, Kiplinger GF, Scholz NE (1971a) Concentrations of propoxyphene in human plasma following repeated oral doses. Toxicol Appl Pharmacol 19: 493–497
Wolen RL, Gruber CM, Kiplinger GF, Scholz NE (1971b) Concentrations of propoxyphene in human plasma following oral, intramuscular, and intravenous administration. Toxicol Appl Pharmacol 19: 480–492
Wolen RL, Ziege EA, Gruber MC (1975) Determination of propoxyphene and norpropoxyphene by chemical ionization mass fragmentography. Clin Pharmacol Ther 17: 15–20
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brøsen, K., Gram, L.F., Schou, J. et al. Dextropropoxyphene kinetics after single and repeated oral doses in man. Eur J Clin Pharmacol 29, 79–84 (1985). https://doi.org/10.1007/BF00547373
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00547373